Can Carboplatin Be Safely Omitted in Neoadjuvant HER2-Positive Breast Cancer? Evidence, Patient Selection, and Practice Impact

from TheBrief.Health · host TheBrief.Health

Reconsidering carboplatin in neoadjuvant HER2-positive breast cancer may reduce toxicity and resource use while maintaining outcomes, emphasizing individualized treatment decisions, patient experience, and careful monitoring.

Episode metadata supplied by the publisher feed · Published Apr 27, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Can Carboplatin Be Safely Omitted in Neoadjuvant HER2-Positive Breast Cancer? Evidence, Patient Selection, and Practice Impact

0:00 1:45

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TheBrief.Health?

This episode is 1 minute long.

When was this TheBrief.Health episode published?

This episode was published on April 27, 2026.

Can I download this TheBrief.Health episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!